![]() |
|
|
Vol. 296, Issue 2, 573-583, February 2001
Institute of Pharmacology and Toxicology, Consejo Superior de Investigaciones Científicas, School of Medicine, Universidad Complutense, Madrid, Spain
| |
Abstract |
|---|
|
|
|---|
We have studied and compared the effects of bupivacaine with those induced by a new local anesthetic, IQB-9302, on human cardiac K+ channels hKv1.5, Kv2.1, Kv4.3, and HERG. Both drugs have a close chemical structure, only differing in their N-substituent (n-butyl and cyclopropylmethyl, for bupivacaine and IQB-9302, respectively). Both drugs blocked Kv2.1, Kv4.3, and HERG channels similarly. Bupivacaine inhibited these channels by 48.6 ± 3.4, 45.4 ± 12.4, and 43.1 ± 9.1%, respectively, and IQB-9302 by 48.1 ± 3.3, 36.1 ± 3.7, and 50.3 ± 6.6%, respectively. However, bupivacaine was 2.5 times more potent than IQB-9302 to block hKv1.5 channels (EC50 = 8.9 ± 1.4 versus 21.5 ± 4.7 µM). Both drugs induced a time- and voltage-dependent block of hKv1.5 and Kv2.1 channels. Block of Kv4.3 channels induced by either drug was time- and voltage-dependent at membrane potentials coinciding with the activation of the channels. IQB-9302 produced an instantaneous block of Kv4.3 and hKv1.5 channels at the beginning of the depolarizing pulse that can be interpreted as a drug interaction with a nonconducting state. Bupivacaine and IQB-9302 induced a similar degree of block of HERG channels and induced a steep voltage-dependent decrease of the relative current. These results suggest that 1) bupivacaine and IQB-9302 block the open state of hKv1.5, Kv2.1, Kv4.3, and HERG channels; and 2) small differences at the N-substituent of these drugs do not affect the drug-induced block of Kv2.1, Kv4.3, or HERG, but specifically modify block of hKv1.5 channels.
| |
Introduction |
|---|
|
|
|---|
Local
anesthetics block the generation and conduction of nerve impulses by
inhibiting the current through voltage-gated Na+
channels in the membrane of nerve cells (Hille, 1977
; Hondeghem and
Katzung, 1977
; Strichartz, 1987
). Bupivacaine is a potent amide local
anesthetic widely used for long-lasting epidural anesthesia (Strichartz, 1987
). However, bupivacaine-like local anesthetics are not
selective Na+ channel blockers. In fact, at the
same range of concentrations used in the clinical practice to block the
generation and propagation of nerve action potentials, this type of
local anesthetic also blocks K+ channels
(Valenzuela et al., 1995a
,b
; Lipka et al., 1998
). Moreover, at higher
concentrations, they also block the L-type Ca2+
channels, thus decreasing cardiac contractility and conduction velocity
through the atrioventricular node (Strichartz, 1987
; Sanchez-Chapula,
1988
). Bupivacaine-induced block of K+ channels
has been considered the molecular mechanism by which this drug induces
a prolongation of the QTc interval of the ECG in anesthetized dogs
(Kasten and Martin, 1985
; Wheeler et al., 1988
) and human volunteers
receiving high doses of this anesthetic (Scott et al., 1989
).
hKv1.5, Kv2.1, Kv4.3, and HERG channels are involved in the
repolarization of the human cardiac action potential (Wang et al.,
1993
; Curran et al., 1995
; Firek and Giles, 1995
; Mays et al., 1995
;
Sanguinetti et al., 1995
; Van Wagoner et al., 1997
; Kaab et al., 1998
).
In fact, Kv1.5, Kv4.3, and HERG are considered to be the
cloned counterparts of the IKur,
ITO, and
IKr, respectively (Fedida et al.,
1993
; Wang et al., 1993
, 1999
; Sanguinetti et al., 1995
; Dixon et al.,
1996
; Feng et al., 1997
). Moreover, the presence of mRNA encoding the
expression of Kv2.1 channels as well as the Kv2.1 protein in human
atria has been demonstrated, although there is not a direct
relationship of this channel with a native potassium current
(Van Wagoner et al., 1997
). The pharmacological effects of bupivacaine
on different K+ channels, including
HERG, Kv1.4, Kv4.3, and hKvLQT1+minK have been already
studied after the expression of the corresponding cRNA in
Xenopus oocytes (Lipka et al., 1998
). However, it has been
reported that when studying the effects of lipophilic drugs (such as
bupivacaine) that act from the inside of the cell membrane, the
apparent drug potency is approximately 10 to 100 times lower when using
whole oocyte recordings than cell-free patch recordings (free of yolk)
(Yatani et al., 1993
; Ficker et al., 1998
). Therefore, it would be of
interest to study the effects of bupivacaine on K+ channels expressed in mammalian cells, that
exhibit closer pharmacological responses to human cardiac myocytes than
Xenopus oocytes. IQB-9302 is a new amide type local
anesthetic, chemically related to bupivacaine (Fig.
1), synthesized as a less cardiotoxic
alternative to bupivacaine and with similar potency to block
Na+ channels (Gallego-Sandín et al.,
1999
; Ruiz-Nuño et al., 1999
). In the present study, we have
analyzed the electrophysiological effects of bupivacaine and IQB-9302
on hKv1.5, Kv2.1, Kv4.3, and HERG channels expressed in
mammalian cell lines. Preliminary results have been published in
abstract form (González et al., 2000
).
|
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture.
Stably transfected
Ltk
cells with the gene encoding the
expression of hKv1.5 or Kv2.1 channels were cultured in Dulbecco's modified Eagle's medium with 10% horse serum and 0.25 mg/ml
G418 (GIBCO, Paisley, Scotland, UK) in a 5%
CO2 atmosphere as previously described
(Valenzuela et al., 1995a
, 1996
). Chinese hamster ovary cultures were
grown in Ham's F-12 medium with 10% fetal bovine serum and
transiently transfected with the cDNA encoding the Kv4.3 or
HERG channel (4 µg) and the cDNA encoding the CD8 antigen
(0.5 µg) by use of lipofectAMINE. Before experimental use, cells were incubated with polystyrene microbeads precoated with anti-CD8 antibody
(Dynabeads M450; Dynal, Oslo, Norway). Most of the cells beaded
also had channel expression.
Electrophysiological Recording. The intracellular pipette-filling solution contained 80 mM potassium aspartate, 50 mM KCl, 3 mM phosphocreatine, 10 mM KH2PO4, 3 mM MgATP, 10 mM HEPES-K, and 5 mM EGTA and was adjusted to pH 7.25 with KOH. The bath solution contained 130 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM HEPES-Na, and 10 mM glucose, and was adjusted to pH 7.40 with NaOH. IQB-9302 [1-(cyclopropylmethyl-2',6'-pipecoloxylidide] (gift from Dr. A. Galiano, IQB-Inibsa S.A., Barcelona, Spain) and bupivacaine (Sigma Chemical Co., St. Louis, MO) were dissolved in distilled deionized water.
hKv1.5, Kv2.1, Kv4.3, and HERG currents were recorded at room temperature (20-22°C) using the whole-cell patch-clamp technique (Hamill et al., 1981
.
Maximum hKv1.5 current amplitudes at +60 mV averaged 2.2 ± 0.3 nA, mean uncompensated access resistance was 2.4 ± 0.5 M
, and
cell capacitance was 11.2 ± 0.8 pF (n = 10).
Thus, no significant voltage errors (<5 mV) were expected with the
electrodes used.
In all cases, cells were held at
80 mV. After control data were
obtained, bath perfusion was switched to drug-containing solution. The
effects of drug infusion was monitored with test pulses to +60 mV or to
+30 mV (for HERG currents), applied every 30 s until
steady state was obtained (after ~12 min). Steady-state current-voltage relationships (IV) were obtained by averaging the
current over a small window at the end of 250-ms or 5-s (for HERG currents) depolarizing pulses. Between
80 and
40 mV
only passive linear leak was observed and least-squares fits to these data were used for passive leak correction. Deactivating "tail" currents of hKv1.5 and Kv2.1 channels were recorded at
40 mV and
HERG tail currents were recorded at
60 mV. The activation curve of hKv1.5, Kv2.1, and HERG channels were obtained from
the tail current amplitude measured just after the capacitive
transient. Block of Kv4.3 channels was calculated as the reduction of
the amount of charge crossing the membrane during the application of
250-ms depolarizing pulses from
80 mV to +60 mV (estimated from the
integral of the current). Command potentials, data acquisition, and
measurements were done using the Clampfit program of pClamp 6.0.1, origin 5.0 (Microcal Software, Northampton, MA) and by a custom-made
analysis program.
In the case of hKv1.5 channels, EC50 values were
obtained from f = 1/[1 + (EC50/[D])nH],
where [D] represents the drug concentration and
nH, the Hill coefficient. The apparent
rate constants for binding (k) and unbinding (l)
were obtained from the following equation
|
(1) |
B represents the time constant of
the drug-induced fast initial decline during depolarization to +60 mV.
Thus, k and l were calculated from the fit of
1/
B versus different drug concentrations. For Kv2.1 and
Kv4.3 currents,
B values were obtained from
the monoexponential fit of the
(IControl
IDrug)/IControl ratio.
The dominant time constant of the activation process was analyzed
fitting it to a single exponential, following a procedure previously
described and used for the same purpose (Valenzuela et al., 1995a
|
(2) |
1 and
2
are the system time constants, A1 and
A2 are the amplitudes of each
component of the exponential, and C is the baseline value.
Half-maximal voltages (Eh) and slope
factors (s) of activation of hKv1.5, Kv2.1, and
HERG channels were determined by fitting data with a
Boltzmann equation: y = 1/[1 + exp(
(E
Eh)/s)]. The curve-fitting
procedure used a nonlinear least-squares (Gauss-Newton) algorithm;
results were displayed in linear and semilogarithmic format, together
with the difference plot. Goodness of fit was judged by the
2 criterion and by inspection for systematic
nonrandom trends in the difference plot.
Voltage dependence of block was determined as follows: leak-corrected
current in the presence of drug was normalized to matching control to
yield the fractional block at each voltage (f = 1
IDrug/IControl).
The voltage dependence of block was fitted to the following equation:
|
(3) |
represents the fractional electrical
distance, i.e., the fraction of the transmembrane electrical field
sensed by a single charge at the receptor site and
KD* represents the apparent
dissociation constant at the reference potential (0 mV).
Statistical Methods. Results are expressed as mean ± S.E.M. Direct comparisons between mean values in control conditions versus mean values in the presence of drug for a single variable were performed by a paired Student's t test. ANOVA was used to compare more than two groups. Student's t test was also used to compare two regression lines. Differences were considered significant if the p value was less than 0.05.
| |
Results |
|---|
|
|
|---|
Effects of IQB-9302 and Bupivacaine on hKv1.5 Channels.
Figure
2A shows current records obtained in the
absence and in the presence of 20 µM bupivacaine or IQB-9302. The
holding potential was maintained at
80 mV and 250-ms depolarizing
pulses in duration to membrane potentials between
80 and +60 mV were applied. Tail currents were recorded upon repolarization to
40 mV. At
20 µM, both drugs inhibited hKv1.5 current, bupivacaine being more
potent than IQB-9302 (57.3 ± 2.9%, n = 4 versus
41.6 ± 2.3%, n = 10, p < 0.01, respectively). The effects of both drugs were reversible upon perfusion
of the cells with drug-free external solution (90 ± 3% of the
control values, n = 6, and 82 ± 4%,
n = 9, for bupivacaine and IQB-9302, respectively).
Both anesthetics significantly accelerated the activation kinetics of
the current at +60 mV (1.44 ± 0.08 versus 1.21 ± 0.09 ms,
n = 5, p < 0.05; and 1.28 ± 0.11 versus 0.81 ± 0.01 ms, n = 4, p < 0.01, for bupivacaine and IQB-9302, respectively). The degree of
inhibition of hKv1.5 current was measured at the end of depolarizing
pulses from
80 to +60 mV induced by different bupivacaine and
IQB-9302 concentrations (between 0.2 and 100 µM). Individual data
were fit with the Hill equation to estimate an
EC50 for hKv1.5 current inhibition and a Hill
coefficient. These fits yielded EC50 values of
8.9 ± 1.4 µM (n = 22) and 21.8 ± 4.7 µM
(n = 29, p < 0.01) for bupivacaine and
IQB-9302, and Hill coefficients of 0.88 ± 0.02 and 0.92 ± 0.01, respectively.
|
B). Figure 3, A
and B, show the apparent rate of block (1/
B)
versus bupivacaine and IQB-9302 concentration. The straight lines are
the least-squares fit to the relation 1/
B = k × [D] + l which for
bupivacaine, yielded apparent association (k) and
dissociation (l) rate constants of 2.45 ± 0.19 µM
1 s
1 and 29.1 ± 8.8 s
1 (n = 14),
respectively. The k value for IQB-9302 was similar to that
obtained for bupivacaine (2.07 ± 0.43 µM
1 s
1,
n = 8, p > 0.05), whereas l
was ~2 times faster than that obtained with bupivacaine (56.8 ± 9.2 s
1, n = 8, p < 0.01). These results suggest a more stable
interaction between the receptor and bupivacaine than with IQB-9302 and
explain differences in potency between both drugs. To further analyze the time course of development of block, in Fig. 3, A and B (insets), we represented the ratio between the drug-sensitive current and the
current in control conditions
[(IControl
IDrug)/IControl] during the first 100 ms in the presence of 20 µM bupivacaine or IQB-9302. In the presence of either drug, block developed following a
monoexponential function with time constants of 11.3 ± 0.8 ms (n = 7) and 12.6 ± 1.4 ms (n = 7), respectively. Whereas bupivacaine development of block only
appeared upon depolarization; an initial "instantaneous" component
of block was observed in the presence of IQB-9302 at the beginning of
the depolarizing pulse (t = 0 ms), which averaged
15.3 ± 2.0% (n = 7), and that was followed by
the previously described time-dependent increase in block. In fact,
IQB-9302 induced a higher degree of block measured at the maximum peak
current than that produced by bupivacaine. Thus, block at the maximum
peak current induced by bupivacaine and IQB-9302 contributed by
47.5 ± 4.2% (n = 4) and 77.4 ± 2.4%
(n = 10, p < 0.01), respectively, to
the total amount of block.
|
f) of 22.8 ± 1.6 ms and a slow one
(
s) that averaged 95.9 ± 22.6 ms.
Bupivacaine eliminated the fast component of deactivation, so that
deactivation became a monoexponential process with a time constant of
97.2 ± 19.2 ms (n = 5, p > 0.05 versus the slow time constant obtained under control conditions).
IQB-9302 increased the two time constants from 19.0 ± 3.4 and
57.9 ± 15.0 ms to 28.2 ± 2.9 ms (n = 5, p < 0.05) and 112.5 ± 33.0 ms (n = 5, p > 0.05). Moreover, in the presence of both
IQB-9302 or bupivacaine, an initial rising phase at the beginning of
the tail current was observed, thus indicating the dissociation of the
drug from the receptor at the channel. The slowing of the deactivating
process induced by both drugs produced a "crossover" phenomenon
when the tail currents obtained under control conditions and in the
presence of the drug were superimposed, suggestive of an open channel
block mechanism (Armstrong, 1971
-values, that averaged 0.20 ± 0.02 (n = 14) for bupivacaine. For IQB-9302,
averaged 0.17 ± 0.01 (n = 10, p > 0.05).
Effects of IQB-9302 and Bupivacaine on Kv2.1 Channels.
Figure
4A shows original records of Kv2.1
currents in the absence and in the presence of bupivacaine and
IQB-9302. At 20 µM, bupivacaine and IQB-9302 induced a percentage of
block of Kv2.1 channels that averaged 48.6 ± 3.4%
(n = 6) and 48.1 ± 3.3% (n = 6, p > 0.05), respectively. Both drugs produced a
decrease of the time constant of activation of the current [from
15.5 ± 2.3 to 11.7 ± 2.8 ms (n = 6, p < 0.01) in the absence and in the presence of
bupivacaine, and from 22.5 ± 2.2 to 19.7 ± 2.8 ms
(n = 6, p < 0.05), in the absence and
in the presence of IQB-9302]. In contrast to the effects observed in
hKv1.5 channels, neither drug induced a fast initial decline of the
maximum activated Kv2.1 current, i.e., block did not display time
dependence on the maximum activated outward current. However, as it can
be observed in Fig. 4B, both drugs slowed the time course of
deactivation of Kv2.1 channels. Under control conditions, the
deactivation process was fitted following a biexponential process, with
a fast and a slow time constant of 10.5 ± 0.7 and 54.2 ± 8.1 ms (n = 4), respectively. In the presence of
bupivacaine, the deactivation process was monoexponential with a time
constant of 37.1 ± 5.4 ms (n = 4, p > 0.05 compared with the control
s) and a crossover phenomenon was observed. IQB-9302 also slowed the deactivation process, but at the same concentration than bupivacaine this new local anesthetic slowed the
fast time constant of deactivation (14.8 ± 1.4 versus 18.5 ± 1.2 ms, n = 5, p < 0.05), without
modifying the slow one (77.7 ± 17.0 versus 80.0 ± 16.6 ms,
n = 5, p > 0.05). To calculate the time constant of development of block, in Fig.
5A we represented the ratio between the
drug-sensitive current and the current in control conditions
[(IControl
IDrug)/IControl].
The fit of this ratio to a monoexponential function yielded the time
constant of development of block, which averaged 9.3 ± 0.6 ms
(n = 5) and 11.7 ± 1.3 ms (n = 6, p > 0.05) for bupivacaine and IQB-9302, respectively.
|
|
-values, which averaged 0.16 ± 0.01 (n = 5) for bupivacaine and 0.20 ± 0.03 (n = 4, p > 0.05) for IQB-9302.
Effects of IQB-9302 and Bupivacaine on Kv4.3 Channels.
Figure
6A shows original records of Kv4.3
current after applying 250-ms depolarizing steps from a holding
potential of
80 mV to membrane potentials between
80 and +60 mV in
10-mV steps in the absence and in the presence of 20 µM bupivacaine
or IQB-9302. Both drugs decreased the peak current to a similar extent
[25.3 ± 2.8% (n = 6) and 32.6 ± 3.0%
(n = 7, p > 0.05), in the presence of
bupivacaine and IQB-9302, respectively]. However, their most prominent
effect was an acceleration of the time course of inactivation, which
was faster in the presence of bupivacaine than in the presence of
IQB-9302 (Fig. 6B). The fast time constants of inactivation decreased
from 27.4 ± 3.9 to 9.9 ± 1.4 ms (n = 5, p < 0.01) in the presence of bupivacaine and from
26.8 ± 2.9 to 13.2 ± 1.3 ms (n = 5, p < 0.05) in the presence of IQB-9302, with this
effect being reversible upon washout of the cells with drug-free
external solution. This accelerated decline of the current was
suggestive of an open channel block mechanism, indicating that the
reduction of peak current would be a nonequilibrium measure of block.
Therefore, block of Kv4.3 channels by bupivacaine and IQB-9302 was also
measured as the reduction of the amount of charge crossing the membrane (estimated from the integral of the current) during the application of
250-ms depolarizing pulses from
80 to +60 mV. Bupivacaine and
IQB-9302 produced similar levels of Kv4.3 inhibition, reducing the
integrated current by 45.4 ± 12.4% (n = 6) and
36.1 ± 3.7% (n = 7, p > 0.05),
respectively. Interestingly, the inhibition of the current induced by
bupivacaine measured at the maximum peak current was lower than that
obtained from the inhibition measurements of the integral of the
current (25.3 ± 2.8 versus 45.4 ± 12.4%, n = 5, p < 0.05), whereas IQB-9302 inhibited similarly the maximum peak current than the current integral (32.6 ± 3.0 versus 36.1 ± 3.7%, n = 7, p > 0.05), suggesting that IQB-9302 may block other state of Kv4.3 channels
previous to the open one.
|
B values for bupivacaine and IQB-9302 on Kv4.3
channels were calculated from the fitting of the ratio between the
drug-sensitive current and the current in control conditions
[(IControl
IDrug)/IControl] averaging 6.5 ± 0.7 ms (n = 4) and 7.5 ± 0.8 ms (n = 4, p > 0.05), respectively
(Fig. 7A). As it is observed in Fig. 7A,
although bupivacaine development of block began during the
depolarization, IQB-9302 development of block exhibited an initial
"instantaneous" component at the beginning of the depolarizing
pulse (t = 0 ms), which averaged 19.2 ± 1.0%
(n = 4) and that was followed by the previously
described time-dependent increase in block.
|
-values measured from the inside
of the membrane that averaged 0.11 ± 0.05 (n = 4)
and 0.08 ± 0.04 (n = 4, p > 0.05) for bupivacaine and IQB-9302, respectively (Fig. 7C).
Effects of IQB-9302 and Bupivacaine on HERG
Channels.
Figure 8A shows original
records obtained after applying 5-s depolarizing steps from a holding
potential of
80 mV to membrane potentials between
80 and +50 mV in
10-mV steps in the absence and in the presence of bupivacaine or
IQB-9302 (20 µM). Under control conditions, outward HERG
currents during depolarization are reduced because channels inactivate
faster than they activate (Sanguinetti et al., 1995
). Upon
repolarization, rapid recovery from inactivation preceded deactivation,
resulting in a hooked tail current (Sanguinetti et al., 1995
).
Bupivacaine and IQB-9302 decreased to a similar extent the amplitude of
the current measured at 0 mV, 43.1 ± 9.1% (n = 5) and 50.3 ± 6.6% (n = 5, p > 0.05), respectively. Figure 8B shows tail HERG currents
obtained in the absence and in the presence of 20 µM bupivacaine or
IQB-9302. Deactivation kinetics of HERG channels at
60 mV
after depolarization of the cell membrane to +50 mV exhibited a
biexponential kinetics. Bupivacaine slowed the deactivation time course
from 168.3 ± 22.8 and 845.7 ± 89.8 ms to 260.0 ± 22.5 ms (n = 4, p < 0.01) and 979.0 ± 104.7 ms (n = 4, p < 0.05), without
modifying the contribution of the fast component to the total process
(0.47 ± 0.06 versus 0.43 ± 0.03, in the absence and in the
presence of bupivacaine, n = 4, p > 0.05). However, IQB-9302 did not modify the kinetics of the tail
currents. Figure 9A shows the IV
relationships obtained by plotting the magnitude of the HERG
current amplitude at the end of 5-s pulses as a function of the
membrane potential under control conditions and in the presence of
bupivacaine or IQB-9302 (20 µM). Both drugs inhibited to a similar
extent HERG current at membrane potentials ranging between
20 and +60 mV. Figure 9B shows the activation curves obtained in the
absence and in the presence of bupivacaine or IQB-9302. Both drugs
shifted the activation curve toward hyperpolarizing direction without
modifying its slope. In fact, the Eh
values in the absence and in the presence of bupivacaine averaged
3.1 ± 1.1 and
9.9 ± 1.7 mV, respectively (n = 4, p < 0.05). In the absence and
in the presence of IQB-9302, Eh
averaged
8.0 ± 1.8 and
14.0 ± 2.3 mV (n = 5, p < 0.05). Figure 9C shows the relative tail
current in the presence of bupivacaine or IQB-9302 versus membrane
potential. The relative current steeply decreased in the membrane
potential range coinciding with the HERG channels
activation, suggesting an open channel block mechanism. Similarly to
that observed in Kv4.3 channels, at membrane potentials positive to +15
mV, a slight increase in block was observed, consistent with
-values
of 0.09 ± 0.02 (n = 4) and 0.08 ± 0.04 (n = 6, p > 0.05) in the presence of
bupivacaine and IQB-9302.
|
|
| |
Discussion |
|---|
|
|
|---|
In the present article the effects of bupivacaine and IQB-9302 on hKv1.5, Kv2.1, Kv4.3, and HERG channels expressed in mammalian cells have been analyzed. Both drugs blocked Kv2.1, Kv4.3, and HERG channels to a similar extent, whereas bupivacaine resulted to be 2.5-fold more potent than IQB-9302 to block hKv1.5 channels. To our knowledge, this is the first study in which the effects of bupivacaine have been analyzed on hKv1.5 and Kv2.1 channels.
Effects of Bupivacaine and IQB-9302 on hKv1.5, Kv2.1, Kv4.3, and
HERG Channels.
Block induced by bupivacaine and
IQB-9302 of hKv1.5 channels was time- and voltage-dependent. Both drugs
induced a fast initial decline of the current upon depolarization,
which reached steady state at the end of 250-ms depolarizing pulses.
Although bupivacaine block appeared only upon depolarization,
suggesting a pure open channel block mechanism, IQB-9302 block showed
an initial block previous to the development of block observed during
depolarization, which suggests that this drug also blocks a closed
state of the channel previous to the open one. The superposition of the
tail currents recorded under control conditions and in the presence of
either drug shows a "crossover" between them, indicating fast recovery from block during deactivation, consistent with an open channel block mechanism (Armstrong, 1971
). Block induced by bupivacaine or IQB-9302 of hKv1.5 channels was voltage-dependent, in such a way
that block steeply increased in the range of membrane potentials coinciding with the range of activation of hKv1.5 channels, suggesting that these drugs need that the channels open before they can bind to
their receptor site and block K+ efflux. At
membrane potentials positive to 0 mV, block induced by bupivacaine and
IQB-9302 increased with a shallower slope, consistent with a
-value
of ~0.17. This voltage-dependent block was interpreted to be the
consequence of the effects of the transmembrane electrical field on the
interaction between the cationic form of the drugs
(pKa of ~8.0) and their receptor site at the
channel level, as it has been proposed for bupivacaine enantiomers in hKv1.5 channels (Valenzuela et al., 1995a
).
-value of
~0.17. All these results suggest that bupivacaine and IQB-9302 block
the open state of Kv2.1 channels.
Bupivacaine and IQB-9302 induced a faster inactivation process of the
Kv4.3 current and block increased in an monoexponential manner during
the activation of the channels, reaching a maximum value after ~50
ms, consistent with an open channel block mechanism. However, in the
presence of IQB-9302 an instantaneous block was observed at
t = 0 ms. This initial block, which appears before channel opening averaged 19.2 ± 1.0%, and could be attributed to
the drug interaction with a nonconducting state of the channel. Consistent with this hypothesis, the degree of inhibition of the maximum peak current and the charge by IQB-9302 were similar, whereas
for bupivacaine, both were significantly different, with the charge
inhibition being higher than that of the peak current. However, as
suggested by the further inhibition of the current observed during the
application of depolarizing pulses, it seems that IQB-9302 also binds
to the open state of the channel. Bupivacaine-induced block of Kv4.3
channels expressed in Xenopus oocytes exhibited an
EC50 value of ~33 µM (Lipka et al., 1998
-values of ~0.06.
HERG channels were also sensitive to the effects of
bupivacaine and IQB-9302. The inhibition produced by 20 µM
bupivacaine in the present study is similar to that reported for
HERG channels expressed in Xenopus oocytes (100 µM) (Lipka et al., 1998
of ~0.07). Therefore,
these results seem to suggest that both local anesthetics exhibit a
higher affinity for the open state than for the inactivated state of
the HERG channels.
Bupivacaine and IQB-9302 have the same chemical structure with the
exception that at position 1, bupivacaine exhibits a butyl group and
IQB-9302 a cyclopropylmethyl group (Fig. 1). Degree of block of Kv2.1,
Kv4.3, and HERG channels induced by bupivacaine and IQB-9302
was very close, thus suggesting that both drugs act as nonspecific
blockers of these K+ channels as previously found
for bupivacaine in Xenopus oocytes (Lipka et al., 1998Clinical Implications of the Present Study.
It has been
described that bupivacaine decreases intracardiac conduction velocity
and widens the QRS complex of the electrocardiogram, effects that were
attributed to the inhibition of INa
(Clarkson and Hondeghem, 1985
; Wheeler et al., 1988
). Both in animal
models and in humans, bupivacaine prolonged the duration of the cardiac action potential (Avery et al., 1984
; Kasten and Martin, 1985
; Scott et
al., 1989
; Solomon et al., 1990
) and the QTc interval of the ECG (Scott
et al., 1989
), effects that can, eventually, result in the development
of a polymorphic ventricular tachycardia known as torsades de pointes
(Kasten and Martin, 1985
). Accidental intravascular injection of
bupivacaine can result in transient plasma concentrations of its free
form of 4 to 12 µg/ml (12-36 µM) (Kotelko et al., 1984
; Sage et
al., 1985
). Since the concentrations of bupivacaine used in the present
study are within this range, it can be proposed that the prolongation
of the QTc interval observed in patients who have received an overdose
of bupivacaine can be explained by the blockade of several cardiac
K+ channels (Scott et al., 1989
). In the present
experiments, IQB-9302 blocked human cloned potassium channels Kv2.1,
Kv4.3, and HERG similarly to bupivacaine. Therefore, it
would be expected that ventricular cardiotoxicity related to the
blockade of K+ channels would be similar for both
drugs. However, further clinical trials are needed to assess this possibility.
Conclusions. The results shown in the present article indicate that small differences at the N-substituent of bupivacaine-like local anesthetics do not affect the degree of block of Kv2.1, Kv4.3, or HERG channels, although specifically modify block of hKv1.5 channels, suggesting that hKv1.5 channels are more sensitive to changes in the N-substituent than Kv2.1, Kv4.3, or HERG channels.
| |
Acknowledgments |
|---|
We thank Guadalupe Pablo and Jose Luis Llorente for excellent technical assistance.
| |
Footnotes |
|---|
Accepted for publication October 30, 2000.
Received for publication July 31, 2000.
This study was supported by Comision Interministerial de Ciencia y Tecnologia SAF98-0058 (to C.V.), Comision Interministerial de Ciencia y Tecnologia SAF99-0069 (to J.T.), CAM 08.4/0016198 (to E.D.), and U.S.-Spain Science and Technology Program 98131 (to C.V.) Grants.
Send reprint requests to: Teresa González, B.S., Institute of Pharmacology and Toxicology, CSIC, School of Medicine, Universidad Complutense, 28040 Madrid, Spain. E-mail: carmenva{at}eucmax.sim.ucm.es
| |
Abbreviations |
|---|
IKur, ultrarapid
delay rectifier potassium current;
ITO, transient outward potassium current;
IKr, rapid delay rectifier potassium current;
IV, current-voltage
relationship;
B, time constant of block;
, fractional
electrical distance;
Eh, voltage at which
50% of the channels are open.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. Felleiter, P. Lierz, and J. Graf The Effects of Local Anesthetics on Bile Flow, Potassium Equilibrium and Oxygen Consumption in the Perfused Rat Liver Anesth. Analg., February 1, 2006; 102(2): 473 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yun Cho, E. A. Beckett, S. A. Baker, I. Han, K. J. Park, K. Monaghan, S. M. Ward, K. M. Sanders, and S. D. Koh A pH-sensitive potassium conductance (TASK) and its function in the murine gastrointestinal tract J. Physiol., May 15, 2005; 565(1): 243 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Friederich, A. Solth, S. Schillemeit, and D. Isbrandt Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1T8A Br. J. Anaesth., January 1, 2004; 92(1): 93 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Kindler, M. Paul, H. Zou, C. Liu, B. D. Winegar, A. T. Gray, and C. S. Yost Amide Local Anesthetics Potently Inhibit the Human Tandem Pore Domain Background K+ Channel TASK-2 (KCNK5) J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 84 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gonzalez, R. Navarro-Polanco, C. Arias, R. Caballero, I. Moreno, E. Delpon, J. Tamargo, M. M. Tamkun, and C. Valenzuela Assembly with the Kvbeta 1.3 Subunit Modulates Drug Block of hKv1.5 Channels Mol. Pharmacol., December 1, 2002; 62(6): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||